P-637. Underlying Medical Conditions in Children 8 to <20 Months of Age Hospitalized with Respiratory Syncytial Virus

Open Forum Infectious Diseases 2026 Open access

Read full text
Authors: Julia S. Bratic, Tess Stopczynski, Leila C. Sahni, Pedro A. Piedra, Laura S Stewart, Marian G. Michaels, John G. Williams, Rangaraj Selvarangan, Jennifer E. Schuster, Daniel C. Payne, Mary Allen Staat, Eileen J. Klein
+7 more Janet A. Englund, Geoffrey A. Weinberg, Peter G Szilagyi, Ariana P. Toepfer, Heidi L. Moline, Natasha Halasa, Julie A. Boom
DOI: 10.1093/ofid/ofaf695.850
Cited by: 0

Abstract

Abstract Background Nirsevimab, a highly effective monoclonal antibody, is recommended for all infants < 8 months of age and high-risk patients 8 to < 20 months of age with chronic lung disease (CLD) of prematurity, cystic fibrosis (CF), severe immunocompromise or who are American Indian/Alaska Native (AI/AN) to prevent RSV.1,2 Other children with underlying medical conditions (UMCs) may also benefit from nirsevimab. We characterized the clinical course of RSV-associated hospitalization in children with UMCs by nirsevimab eligibility.Figure 1.Underlying medical conditions1 for hospitalized children with at least one underlying medical condition aged 8 to

Fields of Study & Subjects

Respiratory viral infections research Pneumonia and Respiratory Infections Neonatal Respiratory Health Research

Publication details

Journal / source
Open Forum Infectious Diseases
Volume
13
Issue
Supplement_1
Publication date
1 January 2026
Language
EN